BRIEF-Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial

Reuters
Mar 19
BRIEF-Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial

March 19 (Reuters) - Eli Lilly and Co LLY.N:

  • ELI LILLY: RETATRUTIDE SHOWED SIGNIFICANT REDUCTIONS IN A1C & WEIGHT IN FIRST PHASE 3 TRIAL FOR TYPE 2 DIABETES TREATMENT

  • ELI LILLY: RETATRUTIDE LOWERED A1C BY AVERAGE OF 1.7%-2.0% ACROSS DOSES AT 40 WEEKS IN TRANSCEND-T2D-1 TRIAL

  • ELI LILLY: PARTICIPANTS TAKING RETATRUTIDE 12 MG LOST AVERAGE OF 36.6 LBS

  • ELI LILLY: NO WEIGHT LOSS PLATEAU WAS OBSERVED WITH RETATRUTIDE

  • ELI LILLY: RETATRUTIDE SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE ACROSS KEY CARDIOVASCULAR RISK FACTORS

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10